---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335098"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2026-08-05T20:10:04+00:00"
generated_at: "2026-08-05T20:11:46.601869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics reports Q2 2026 net loss of $43.4M; positive interim data for TN-201 and TN-401

## Summary
- Net loss of $43.4M ($0.20 loss per share) vs $23.3M loss in Q2 2025; includes $21.8M impairment charge from GMMC lease termination.
- Cash and equivalents $78.1M as of June 30, 2026; runway extended through Q3 2027 including $10M Alnylam upfront.
- Positive interim data from TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) trials: all evaluable patients showed improvements in hypertrophy and electrical stability.
- Additional data and regulatory discussions on pivotal trial plans for TN-201 and TN-401 expected in Q4 2026.
- Appointed Eric Hyllengren as CFO effective July 13, 2026; TN-301 Phase 2 trial expected to start 2H 2027.

## SEC filing metadata
- accession: 0001193125-26-335098
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2026-08-05T20:10:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/0001193125-26-335098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335098
- JSON: https://secwatch.observer/filing/0001193125-26-335098.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.